Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
32987
Tickers With News
515
Showing Now
50
Top Ticker
AAPL
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.
AbbVie has another blockbuster business emerging.
Wolfe Research Upgrades AbbVie (ABBV)
Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]
AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]
AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.
The pharmaceutical company hopes that another big-time acquisition will pay off.
BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...
AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...
Both of these stocks pay more than double the S&P 500 average of 1.1%.
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.
Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.
The stock is up just 8% this year and could prove to be an undervalued buy.
AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]
AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure o
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence. If cleared, BOTOX Cosmetic would be the first neurotoxin approved in the U.S. for this condition, supported by positive Phase 3 trial data. The filing highlights AbbVie’s push to broaden its aesthetics offerings beyond current BOTOX Cosmetic indications. AbbVie (NYSE:ABBV) is drawing fresh attention to its...
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.
The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.
AbbVie Inc. (ABBV) Q2 2026 Earnings Call July 31, 2026 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of $436.27 billion. Buying
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ’s labeled uses in Europe and add new indications in dermatology and immunology. For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company...
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AbbVie Inc (ABBV) beats expectations with 10.2% revenue growth, raises full-year guidance, and showcases promising pipeline developments despite Humira's decline.
AbbVie Q2 earnings match estimates, but stock dips 4% on Apogee Therapeutics acquisition news amid steady results.
Moby summary of AbbVie Inc.'s Q2 2026 earnings call
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.
The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share
AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics.
AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy.1 With this approval, RINVOQ is now the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.2
AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago, investors were restless. The two drugs carrying the company were doing fine, but everyone already knew that, and the market wanted a new reason to invest. Goldman Sachs went ...
But is that performance sustainable?
